# This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.

> **NCT03573544** · PHASE1,PHASE2 · TERMINATED · sponsor: **OBI Pharma, Inc** · enrollment: 54 (actual)

## Conditions studied

- Metastatic Solid Tumors
- Locally Advanced Solid Tumors

## Interventions

- **DRUG:** OBI-888
- **DRUG:** OBI-888
- **DEVICE:** Globo H IHC Assay

## Key facts

- **NCT ID:** NCT03573544
- **Lead sponsor:** OBI Pharma, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-07
- **Primary completion:** 2022-04-07
- **Final completion:** 2022-04-07
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** OBI-888 no longer fulfills our goal of developing cost-effective therapies for cancer patients
- **Last updated:** 2024-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03573544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03573544, "This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03573544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*